DOJ closes Brilinta investigation

Share this article:

The Department of Justice has closed its investigation into the Plato trials which supported the approval of AstraZeneca's  anti-clotting drug, Brilinta (ticagrelor). The company announced the end of the investigation Tuesday.

The drug was of note during the company's bid to fend off Pfizer's proposed takeover. The firm projected that the anti-clotting drug had the potential to hit $3.5 billion in sales by 2023 if it pursued "broader opportunities."

The FDA approved Brilinta for the treatment of patients with acute coronary syndrome in 2011, but in 2013 the DOJ asked the drugmaker to submit documents about the head-to-head Plato trial which compared Brilinta to clopidogrel, which is also known by the BMS/Sanofi brand name Plavix. Allegations that the data had been manipulated surfaced when adjunct medical professor Victor Serebruney at Johns Hopkins Hospital said the numbers did not add up, and filed a complaint under the False Claims Act.

The Wall Street Journal noted at the time that although the professor specialized in these types of drugs but “didn't assert direct personal knowledge of any wrongdoing.”

The Journal also noted at the time that the complaint was not the only allegation that shadowed the trial. Thomas Marciniak, who headed up the FDA's drug review said the review application was a mess of poor record keeping and was “the worst submission I have encountered for collecting—or at least submitting—information on SAEs,” with SAEs referring to serious adverse events.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies